Xenon Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
XENE Nasdaq 2836 www.xenon-pharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xenon Pharmaceuticals Inc.

Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Dec 7th, 2025 5:08 pm
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 - Dec 5th, 2025 7:00 am
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 4th, 2025 3:20 pm
Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? - Dec 4th, 2025 9:30 am
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? - Dec 3rd, 2025 9:30 am
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 - Dec 3rd, 2025 6:30 am
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 - Nov 25th, 2025 6:30 am
Xenon to Present at Upcoming Investor Conferences - Nov 6th, 2025 6:30 am
Xenon Pharmaceuticals (XENE): Losses Widen 37% Annually, Challenging Bullish Revenue Growth Expectations - Nov 4th, 2025 11:13 pm
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Nov 4th, 2025 7:54 am
Xenon Pharmaceuticals Inc (XENE) Q3 2025 Earnings Call Highlights: Strong Financial Position ... - Nov 3rd, 2025 10:01 pm
Xenon Pharmaceuticals: Q3 Earnings Snapshot - Nov 3rd, 2025 2:32 pm
Xenon Reports Third Quarter 2025 Financial Results & Business Update - Nov 3rd, 2025 2:01 pm
Xenon to Report Q3 2025 Financial Results on November 3, 2025 - Oct 27th, 2025 6:30 am
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer - Oct 16th, 2025 6:30 am
Xenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum - Oct 12th, 2025 4:09 am
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday Amid Tech, AI Strength - Oct 2nd, 2025 6:58 am
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain - Sep 25th, 2025 2:01 pm
Design Therapeutics Appoints Justin Gover to Board of Directors - Sep 10th, 2025 2:01 pm
Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? - Sep 10th, 2025 9:30 am